GlassScriptPhysician profile
Nidal Shawahin
NPI 1245236884
$21,513.80
in general payments reported to CMS, 2019-2025
54 companies · $851 in 2025
The $851 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,487 · 2020: $3,249 · 2021: $3,911 · 2022: $3,204 · 2023: $3,437 · 2024: $3,376 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,517 · Education: $134 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,516.95 |
| Education | $133.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,868.92 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,690.89 | 2019-2025 | |
| Abbvie INC. | $1,653.99 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Janssen Pharmaceuticals, INC | $1,617.54 | 2019-2025 | Spravato, Xarelto |
| Novo Nordisk INC | $1,606.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,581.08 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $987.22 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $838.60 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $816.33 | 2019-2024 | Jardiance, Tradjenta, Trijardy Xr |
| Sanofi-Aventis U.S. LLC | $638.86 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $609.88 | 2021-2025 | |
| Astellas Pharma US INC | $570.90 | 2019-2024 | Veozah, Myrbetriq |
| Allergan, INC. | $556.44 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $502.09 | 2021-2025 | Ajovy, Austedo Xr, Austedo |
| Amgen INC. | $491.91 | 2019-2025 | Repatha, Otezla, Evenity |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidal Shawahin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.